138614-30-9
中文名称
艾替班特乙酸盐
英文名称
HOE-140
CAS
138614-30-9
分子式
C59H89N19O13S.C2H4O2
分子量
1364.59
MOL 文件
138614-30-9.mol
更新日期
2024/05/27 09:51:34
138614-30-9 结构式
基本信息
中文别名
艾替班特乙酸盐艾替班特 ACETATE
醋酸艾替班特(艾替班特乙酸盐,HOE 140)
D-精氨酸基-L-精氨酸基-L-脯氨酰基-(4R)-4-羟基-L-脯氨酰基糖基-3-(2-噻吩基)-L-丙氨酰基-L-丝氨酰-(3R)-1,2,3,4-四氢-3-异喹啉羰基-(2S,3aS,7aS)-八氢-1H-吲哚-2-羰基-L-精氨酸 乙酸盐
英文别名
FirazyrCS-1399
HOE 140 Acetate
lcatibant Acetate
HOE-140 (Icatibant)
HOE140
ICATIBANT
HOE 140
HOE 140 SYNTHETIC >99% SELECTIVE B2 BRAD YKIN
d-arg-l-arg-l-pro-l-hyp-gly-l-(2-thienyl)ala-l-ser-d-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-l-(2α,3β,7aβ)-octahydro-1h-indole-2-carbonyl-l-arg
Icatibant acetate, D-Arg-L-Arg-L-Pro-L-Hyp-Gly-L-(2-thienyl)Ala-L-Ser-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2α,3β,7aβ)-octahydro-1H-indole-2-carbonyl-L-Arg
(2S)-2-[[(3aS,7aS)-1-[2-[(2S)-2-[[(2S)-2-[[2-[[(4R)-1-[1-[2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-yl-propanoyl]amino]-3-hydroxy-propanoyl]3,4-dihydro-1H-isoquinoline-3-carbonyl]2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
艾替班特乙酸盐价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | S5695 | 艾替班特乙酸盐 Icatibant Acetate | 138614-30-9 | 2mg | 1204.11元 |
| 2024/04/30 | S5695 | Icatibant Acetate | 138614-30-9 | 25mg | 7126.16元 |
| 2024/04/30 | S5695 | Icatibant Acetate | 138614-30-9 | 100mg | 16954.2元 |
常见问题列表
生物活性
Icatibant Acetate是bradykinin B2受体的拮抗剂，可用于治疗遗传性血管性水肿。靶点
| Target | Value |
|
bradykinin B2 receptor
() |
体外研究
Icatibant (10-30 μM) potentiates angiotensin III, but not angiotensin II (contraction mediated by angiotensin AT1 receptors), and Lys-des-Arg9-bradykinin, but not des-Arg9-bradykinin (effects mediated by the bradykinin B1 receptors).
体内研究
Icatibant (10-30 μM) potentiates angiotensin III, but not angiotensin II (contraction mediated by angiotensin AT1 receptors), and Lys-des-Arg9-bradykinin, but not des-Arg9-bradykinin (effects mediated by the bradykinin B1 receptors).
| Animal Model: | Female mice of the CBA/J (H-2 k ) strain. |
| Dosage: | 0.06, 0.3, or 1.5 mg/kg. |
| Administration: | Subcutaneous administration twice daily. |
| Result: | The length of the large intestine was 93.6±6.8 mm with the 1.5 mg/kg dosage and 94.0±4.1 mm with the 0.3 mg/kg dosage , showing a significant preventive effect on shortening. |